Cosentyx® (secukinumab) – New indication, expanded indication
On December 23, 2021, Novartis announced the FDA approval of Cosentyx (secukinumab), for the treatment of active enthesitis-related arthritis (ERA) in patients 4 years of age and older.
Download PDF
